{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:44:20Z","timestamp":1773661460298,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009748","name":"Ernhold Lundstr\u00f6m Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009748","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011077","name":"Sk\u00e5ne University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011077","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hulda Ahlmroth Foundation"},{"name":"Swedish Government"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bpgastro.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.bpg.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T23:00:14Z","timestamp":1469833214000},"page":"105-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacological secondary prevention in patients with mesenterial artery atherosclerosis and arterial embolism"],"prefix":"10.1016","volume":"31","author":[{"given":"Anders","family":"Gotts\u00e4ter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2016.07.004_bib1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2016.07.004_bib2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.bpg.2016.07.004_bib3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1056\/NEJMra1503884","article-title":"Mesenteric ischemia","volume":"374","author":"Clair","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2016.07.004_bib4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s11605-013-2139-z","article-title":"Symptomatic mesenteric atherosclerotic disease \u2013 lessons learned from the diagnostic workup","volume":"17","author":"Bj\u00f6rnsson","year":"2013","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.bpg.2016.07.004_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/bjs.6819","article-title":"Mid-term outcome of endovascular revascularization for chronic mesenteric ischemia","volume":"97","author":"Dias","year":"2010","journal-title":"Br J Surg"},{"key":"10.1016\/j.bpg.2016.07.004_bib6","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jvir.2014.07.003","article-title":"Recanalization of chronic total occlusions of the superior mesenteric artery in patients with chronic mesenteric ischemia: technical and clinical outcomes","volume":"25","author":"Grilli","year":"2014","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.bpg.2016.07.004_bib7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.amjcard.2009.10.018","article-title":"Thromboembolism in atrial fibrillation","volume":"105","author":"Menke","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.bpg.2016.07.004_bib8","first-page":"865","article-title":"Thromboembolism associated with atrial fibrillation as a cause of limb and organ ischemia","volume":"22","author":"Wasilewska","year":"2013","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.bpg.2016.07.004_bib9","doi-asserted-by":"crossref","first-page":"S1150","DOI":"10.1161\/circ.120.suppl_18.S1150-b","article-title":"Unique atrial fibrillation subpopulations: thromboembolic destination predicts recurrence rates and survival","volume":"120","author":"Gosk-Bierska","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.bpg.2016.07.004_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2796.2006.01613.x","article-title":"Fatal nonocclusive mesenteric ischaemia: population-based incidence and risk factors","volume":"259","author":"Acosta","year":"2006","journal-title":"J\u00a0Intern Med"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.bpg.2016.07.004_bib11","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.bpg.2016.07.004_bib12","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehr211","volume":"32","author":"Tendera","year":"2011","journal-title":"Eur Heart J"},{"issue":"Suppl.","key":"10.1016\/j.bpg.2016.07.004_bib13","doi-asserted-by":"crossref","first-page":"e669S","DOI":"10.1378\/chest.11-2307","article-title":"Antithrombotic therapy in peripheral artery disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Alonso-Coello","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.bpg.2016.07.004_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.bpg.2016.07.004_bib15","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2016.07.004_bib16","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2016.07.004_bib17","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2016.07.004_bib18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.bpg.2016.07.004_bib19","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.bpg.2016.07.004_bib20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease","volume":"52","author":"Belch","year":"2010","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.bpg.2016.07.004_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.semvascsurg.2009.12.005","article-title":"Open surgical treatment for chronic mesenteric ischemia in the endovascular era: when it is necessary and what is the preferred technique","volume":"23","author":"Oderich","year":"2010","journal-title":"Semin Vasc Surg"},{"key":"10.1016\/j.bpg.2016.07.004_bib22","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2016.07.004_bib23","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.bpg.2016.07.004_bib24","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European heart rhythm association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.bpg.2016.07.004_bib25","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2016.07.004_bib26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban vs.warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2016.07.004_bib27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ahj.2015.06.020","volume":"170","author":"Geller","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.bpg.2016.07.004_bib28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.bpg.2016.07.004_bib29","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1111\/jth.12970","article-title":"New strategies for effective treatment of vitamin K antagonist-associated bleeding","volume":"13","author":"Yates","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.bpg.2016.07.004_bib30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2016.07.004_bib31","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase I trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2016.07.004_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1586\/17474086.2016.1135046","article-title":"Andexanet\u00a0alfa for the reversal of Factor Xa inhibitor related anticoagulation","volume":"9","author":"Ghadimi","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bpg.2016.07.004_bib33","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(14)61212-5","article-title":"Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2016.07.004_bib34","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.bpg.2016.07.004_bib35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.bpg.2016.07.004_bib36","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should \u03b2-blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2016.07.004_bib37","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis Society (EAS). ESC\/EAS guidelines for the management of dyslipidaemias","volume":"32","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.bpg.2016.07.004_bib38","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2016.07.004_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.bpg.2016.07.004_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacl.2015.01.001","article-title":"Understanding PCSK9 and anti-PCSK9 therapies","volume":"9","author":"McKenney","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.bpg.2016.07.004_bib41","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.bpg.2016.07.004_bib42","first-page":"CD006103","article-title":"Nicotine receptor partial agonists for smoking cessation","volume":"5","author":"Cahill","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpg.2016.07.004_bib43","first-page":"435","article-title":"Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence","volume":"10","author":"Burke","year":"2016","journal-title":"Patient Prefer Adher"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691816300506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691816300506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T16:07:03Z","timestamp":1718726823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691816300506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1521691816300506"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2016.07.004","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological secondary prevention in patients with mesenterial artery atherosclerosis and arterial embolism","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}